Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells.

Growing evidence suggests that Stat3 contributes to chemoresistance. However, the impact of chemotherapy on Stat3 activity is unclear. We found that paclitaxel activated Stat3 in the human lung cancer cell lines PC14PE6AS2 (AS2) and H157, whereas it reduced Stat3 activation in A549 and H460 cells. Pretreatment of AS2 and H157 cells with rotenone, an inhibitor of mitochondrially produced reactive oxygen species (ROS), or carbonyl cyanide p-(trifluoromethoxy)-phenylhydrazone (FCCP), a mitochondrial uncoupler, suppressed the paclitaxel-induced activation of Stat3. Uncoupling protein 2 (UCP-2), located in the inner membrane of the mitochondria, can reduce ROS production in conditions of oxidative stress. UCP-2 protein expression in the four cancer cell lines was higher than that in normal lung epithelial cells (NL-20), but its expression was lower in AS2 and H157 cells relative to A549 and H460 cells. Silencing high UCP-2 expression with small interfering RNA (siRNA) in A549 and H460 cells restored paclitaxel-induced Stat3 activation. In addition, paclitaxel-induced Stat3 activation led to the upregulation of survivin and Mcl-1, which in turn facilitated cell survival. Moreover, the CL1-5 subline had lower UCP-2 expression relative to the parental CL1-0 cells. Treatment with paclitaxel activated Stat3 in CL1-5 but not in CL1-0 cells, whereas in CL1-5 cells, the overexpression of UCP-2 with complementary DNA (cDNA) blocked Stat3 activation. In lung cancer patients, low UCP-2 expression in cancer cells was a predictor of a poor response to chemotherapy. Therefore, UCP-2 modulates the ROS/Stat3 signaling pathway and response to chemotherapy treatment in lung cancer cells. Targeting UCP-2, ROS and Stat3 pathways may improve anticancer therapies.

[1]  D. Prockop,et al.  Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  T. Crook,et al.  Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells , 2012, Cell Death and Disease.

[3]  Bo Liu,et al.  Mitochondrial ROS generation for regulation of autophagic pathways in cancer. , 2011, Biochemical and biophysical research communications.

[4]  R. Mukhopadhyaya,et al.  Uncoupling Protein 2 Negatively Regulates Mitochondrial Reactive Oxygen Species Generation and Induces Phosphatase-Mediated Anti-Inflammatory Response in Experimental Visceral Leishmaniasis , 2011, The Journal of Immunology.

[5]  Ming Zhou,et al.  B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation , 2011, Molecular Cancer Therapeutics.

[6]  D. Frank,et al.  Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling , 2010, Molecular Pharmacology.

[7]  S. Dairkee,et al.  Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer , 2010, Cell Death and Disease.

[8]  R. Kurzrock,et al.  Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2010, Nature Reviews Clinical Oncology.

[9]  G. Baffy.  Uncoupling protein-2 and cancer. , 2010, Mitochondrion.

[10]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[11]  P. Tsai,et al.  The IL-8 Production by Streptococcal Pyrogenic Exotoxin B , 2009, Experimental biology and medicine.

[12]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[13]  P. Fawcett,et al.  Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.

[14]  Jing Yi,et al.  Cancer cell killing via ROS: To increase or decrease, that is the question , 2008, Cancer biology & therapy.

[15]  M. Andreeff,et al.  The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. , 2008, Cancer research.

[16]  J. Wands,et al.  The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. , 2008, Cancer research.

[17]  E. Moon,et al.  Paclitaxel Induces Vascular Endothelial Growth Factor Expression through Reactive Oxygen Species Production , 2008, Pharmacology.

[18]  U. Hengge,et al.  Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. , 2008, Cellular signalling.

[19]  L. Gill,et al.  Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria , 2007, Molecular Cancer Therapeutics.

[20]  H. Pelicano,et al.  Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. , 2007, Cancer research.

[21]  F. Meyskens,et al.  UC Irvine UC Irvine Previously Published Works Title Reactive oxygen species : a breath of life or death ? , 2007 .

[22]  V. Gonzalez,et al.  Calpain inhibition stimulates caspase-dependent apoptosis induced by taxol in NIH3T3 cells. , 2007, Experimental cell research.

[23]  S. Winograd-Katz,et al.  Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor , 2006, Oncogene.

[24]  Helen H. W. Chen,et al.  Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion , 2006, Oncogene.

[25]  F. Goldwasser,et al.  Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo , 2006, International journal of cancer.

[26]  J. Wands,et al.  Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. , 2006, Carcinogenesis.

[27]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[28]  Catherine Jones,et al.  Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[29]  N. Jing,et al.  Targeting Stat3 in cancer therapy. , 2005, Anti-cancer drugs.

[30]  E. Shimizu,et al.  Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. , 2005, Oncology reports.

[31]  J. Wands,et al.  Expression of Uncoupling Protein-2 in Human Colon Cancer , 2004, Clinical Cancer Research.

[32]  S. Chung,et al.  Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[33]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[34]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  Masato Kubo,et al.  Suppressors of cytokine signaling and immunity , 2003, Nature Immunology.

[36]  Takashi Takahashi,et al.  Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. , 2003, The American journal of pathology.

[37]  J. Turkson,et al.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.

[38]  T. Soussi.  p53 mutations and resistance to chemotherapy: A stab in the back for p73. , 2003, Cancer cell.

[39]  N. Holbrook,et al.  Cellular response to oxidative stress: Signaling for suicide and survival * , 2002, Journal of cellular physiology.

[40]  Lichuan Yang,et al.  Measurements of ATP in mammalian cells. , 2002, Methods.

[41]  J. Shih,et al.  Global analysis of gene expression in invasion by a lung cancer model. , 2001, Cancer research.

[42]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[43]  Bin Liu,et al.  Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. , 2000, The Journal of pharmacology and experimental therapeutics.

[44]  J. Ting,et al.  Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism , 2000, Cancer Immunology, Immunotherapy.

[45]  Cheng-Ta Yang,et al.  ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. , 2000, Cancer research.

[46]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[47]  M. Trush,et al.  Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. , 1998, Biochemical and biophysical research communications.

[48]  B. Cochran,et al.  Activation of the JAK-STAT pathway by reactive oxygen species. , 1998, American journal of physiology. Cell physiology.

[49]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[50]  M. Högström,et al.  Methods in laboratory investigation. Exclusion of trypan blue from microcarriers by endothelial cells: an in vitro barrier function test. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[51]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.